Hemant Surgical Industries Ltd
The Company at its meeting held today i.e., May 27, 2026 has entered into Share Purchase Agreement (''SPA'') for acquisition of 66.66% equity shareholding of Lifesenz Cancer Labs Private ....
M&A
◆ Monitor Closely
MEDIUM RISK
📅 Filed on BSE: 27 May 2026, 06:10 PM IST · BSE ID: 99e47c72-1c22-4007-b2bb-d34759d98082
View Original BSE Filing (PDF)
💡
In Simple Terms
Hemant Surgical is buying a 66.66% stake in Lifesenz Cancer Research for Rs. 19,99,80,000 to expand in healthcare.
🤖 AI Summary
- Hemant Surgical Industries Ltd entered a Share Purchase Agreement to acquire 66.66% of Lifesenz Cancer Research Labs Private Limited.
- The acquisition cost for the 66.66% stake is Rs. 19,99,80,000, to be paid in cash.
- The transaction is classified as a related party transaction, undertaken at arm's length based on a valuation report.
- Lifesenz Cancer Research Labs, a healthcare entity, reported Turnover of Rs. 56.75 Lakhs and PAT of Rs. (74.76) Lakhs for F.Y. 24-25.
- The acquisition is slated for completion on or before September 30, 2026, making Lifesenz a subsidiary.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Cost of Acquisition
Rs. 19,99,80,000/-
Percentage of Shareholding Acquired
66.66%
Lifesenz F.Y. 24-25 Turnover
Rs. 56.75 Lakhs
Lifesenz F.Y. 24-25 PAT
Rs. (74.76) Lakhs
Lifesenz F.Y. 24-25 Net Worth
Rs. (221.84) Lakhs
🏢 How This Affects the Company
This acquisition is intended to expand and strengthen Hemant Surgical Industries' presence in the healthcare and cancer diagnostic support segment.
Hemant Surgical will incur a cash outflow of Rs. 19,99,80,000 for the acquisition. Lifesenz reported a Turnover of Rs. 56.75 Lakhs and a PAT of Rs. (74.76) Lakhs for F.Y. 24-25.
Upon completion, Lifesenz Cancer Research Labs Private Limited will become a subsidiary, integrating its cancer research and diagnostic support services into Hemant Surgical's operations.
The acquisition is identified as a related party transaction, though stated to be undertaken at arm's length pursuant to a valuation report. Lifesenz Cancer Research Labs recorded a negative net worth of Rs. (221.84) Lakhs for F.Y. 24-25.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders as the company has entered into a Share Purchase Agreement.
👤
Who Is Affected
Shareholders of Hemant Surgical Industries Ltd are affected by the company's decision to utilize Rs. 19,99,80,000 in cash for this acquisition, which is a related party transaction.
🔍
Management Signal
The decision indicates management's intent to expand into the cancer research and diagnostic support segment through acquisitions, despite the target entity's current financial performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Official announcement of the acquisition completion on or before September 30, 2026.
Hemant Surgical's next financial results — assess balance sheet and cash position post-acquisition.
Future disclosures regarding Lifesenz's operational and financial performance as a subsidiary.
MEDIUM RISK
Acquiring a related party with negative profitability and net worth introduces integration and financial risks.
💡 Investor Takeaway
Hemant Surgical Industries Ltd will acquire 66.66% of Lifesenz Cancer Research Labs Private Limited for Rs. 19,99,80,000 in cash. Lifesenz reported F.Y. 24-25 Turnover of Rs. 56.75 Lakhs, PAT of Rs. (74.76) Lakhs, and a negative Net worth of Rs. (221.84) Lakhs.
⚖️ Strengths & Concerns
✅ Positives
- Strategic expansion into the healthcare and cancer diagnostic support segment diversifies Hemant Surgical's business presence.
- The acquisition is proposed to be undertaken at arm’s length based on a valuation report from a Registered Valuer.
⚠️ Concerns
- Lifesenz Cancer Research Labs reported a negative PAT of Rs. (74.76) Lakhs for F.Y. 24-25, indicating it is currently unprofitable.
- The target entity had a negative net worth of Rs. (221.84) Lakhs for F.Y. 24-25.
❓ Frequently Asked Questions
What is the acquisition cost for Hemant Surgical Industries of Lifesenz Cancer Research?
Hemant Surgical Industries Ltd will acquire 66.66% equity shareholding of Lifesenz Cancer Research Labs Private Limited for Rs. 19,99,80,000.
Is the acquisition of Lifesenz Cancer Research Labs Private Limited a related party transaction?
Yes, the proposed acquisition falls within related party transaction(s) as existing shareholders/directors of Lifesenz are also promoters/directors/shareholders of Hemant Surgical Industries Ltd.
What were Lifesenz Cancer Research Labs Private Limited's financial results for F.Y. 24-25?
For F.Y. 24-25, Lifesenz Cancer Research Labs Private Limited reported a Turnover of Rs. 56.75 Lakhs, a PAT of Rs. (74.76) Lakhs, and a Net worth of Rs. (221.84) Lakhs.
What is the expected timeline for the completion of the acquisition?
The indicative time period for the completion of the acquisition is on or before September 30, 2026.
Questions based on this BSE filing only. For information purposes.